BORTEZOMİB-TALİDOMİD-DEKSAMETAZON(VTD) PROTOKOLÜ
Kaynaklar:
1-Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, et al: Multiple myeloma: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 28 (Suppl 4):iv52–iv61. 2017.
2- Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, Fonseca R, Stewart AK, Harousseau JL, Dimopoulos M, et al: Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma workshop consensus panel 2. Blood. 117:4696–4700. 2011.
3- Anderson KC: The 39th David A. Karnofsky Lecture: Bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol. 30:445–452. 2012.
4- Palumbo A and Anderson K: Multiple myeloma. N Engl J Med. 364:1046–1060. 2011.
5- Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, et al: Multiple myeloma, version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 15:230–269. 2017.
6- Mateos MV, Ocio EM, Paiva B, Rosiñol L, Martínez-López J, Bladé J, Lahuerta JJ, García-Sanz R and San Miguel JF: Treatment for patients with newly diagnosed multiple myeloma in 2015. Blood Rev. 29:387–403. 2015.
7- Rajkumar SV: Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 91:719–734. 2016.
8- Dmoszynska A, Walter-Croneck A, Usnarska-Zubkiewicz L, Stella-Holowiecka B, Walewski J, Charliński G, Jedrzejczak W, Wiater E, Lech-Maranda E, Dytfeld D, et al: Recommendations of polish myeloma group concerning diagnosis and therapy of multiple myeloma and other plasmacytic dyscrasias for 2015. Acta Hematol Pol. 46:159–211.
9- Kyle RA and Rajkumar SV: Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 23:3–9. 2009.
10- Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, et al: International staging system for multiple myeloma. J Clin Oncol. 23:3412–3420. 2005.
11- Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, et al: Revised international staging system for multiple myeloma: A report from international myeloma working group. J Clin Oncol. 33:2863–2869. 2015.
12- Voorhees PM and Usmani SZ: The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy. Clin Adv Hematol Oncol. 14:719–728.
13- Hari P: Recent advances in understanding multiple myeloma. Hematol Oncol Stem Cell Ther. 10:267–271. 2017.
14- Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, Doyen C, Garderet L, Randriamalala E, Araujo C, et al: Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. 118:5752–5758. 2011.
15- Moreau P, Hulin C, Macro M, Caillot D, Chaleteix C, Roussel M, Garderet L, Royer B, Brechignac S, Tiab M, et al: VTD is superior to VCD prior to intensive therapy in multiple myeloma: Results of the prospective IFM2013-04 trial. Blood. 127:2569–2574. 2016.
